← board
PTHS
distress 5/10 · elevated risk$25.90-2%today-31% from 52w high
Revenue
$11M
Liquidity
$32M
Runway
0.9 yrs
Shares 1y
+14%
Price & events
+6.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-3.0%
1W
-12.2%
1M
+11.6%
3M
+4.6%
6M
+18.4%
1Y
+106.4%
2Y
—
5Y
-46.0%
All
Overview
- Market Cap
- $90.02M
- Volume
- 2.08K
- 52 Week Range
- $18.18 – $37.42
- Total Shares
- 3.48M
- Float Shares
- 1.39M
- Short %
- 1.62%
- % Held by Insiders
- 53.77%
- % Held by Institutions
- 35.57%
- RVOL
- 0.06x
- Beta
- 3.13
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- June 4, 2026conferencedata presentationsecondaryCEO Scott Plesha to present and participate in investor meetings at Jefferies conference.SEC 8-K
- 2025-12-23partnershipXeglyze (abametapir) · Acquired Xeglyze from Hatchtech for $1.8M.SEC 8-K
- 2025-11-01partnershipXEPI · Acquisition of XEPI, an FDA-approved topical treatment for impetigoSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $58 (+123% upside) · 7 analysts
- 2026-05-15OppenheimerOutperform
- 2026-04-01Cantor FitzgeraldOverweight
- 2026-03-20OppenheimerOutperform
- 2026-03-19HC Wainwright & Co.Buy
- 2026-02-27Piper SandlerOverweight
- 2026-02-26Roth CapitalBuy
Competitors
- none identified
Recent news
- 2026-07-20Press Release: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction With the Close of the Merger With Pelthos Therapeutics and Concurrent $50.1 Million Private Placement - 富途牛牛
- 2026-07-19Pelthos Therapeutics Inc. (PTHS) reports Q1 loss, beats revenue estimates - MSN
- 2026-07-18Pelthos Therapeutics Inc. (PTHS) reports Q1 loss, beats revenue estimates - MSN
- 2026-07-18Pelthos Therapeutics Inc. (PTHS) reports Q1 loss, beats revenue estimates - MSN
- 2026-07-10Pelthos Therapeutics Inc. (PTHS) reports Q1 loss, beats revenue estimates - MSN
- 2026-07-07Insider Sale: Director at $PTHS Sells 24 Shares - Moomoo
- 2026-07-07Insider Sale: Director at $PTHS Sells 24 Shares - Quiver Quantitative
- 2026-07-07Pelthos Therapeutics (PTHS) director logs small 10b5-1 share sale for tax obligations - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.